Quarterly report pursuant to Section 13 or 15(d)

Commitments And Contingencies (Schedule of Investments Under Securities Purchase Agreement And RELO) (Details)

v2.4.0.6
Commitments And Contingencies (Schedule of Investments Under Securities Purchase Agreement And RELO) (Details) (USD $)
0 Months Ended 0 Months Ended 3 Months Ended 3 Months Ended
Dec. 07, 2012
Dec. 04, 2012
Mar. 31, 2011
Jan. 19, 2011
Jun. 30, 2010
Feb. 12, 2010
Oct. 23, 2009
Sep. 21, 2009
Jun. 05, 2009
Mar. 20, 2008
Dec. 18, 2007
May 13, 2006
Dec. 02, 2005
Aug. 08, 2005
May 10, 2001
Mar. 31, 2013
Dec. 31, 2012
Jan. 19, 2011
Teva Pharmaceutical Industries, Ltd. [Member]
Sep. 21, 2009
Teva Pharmaceutical Industries, Ltd. [Member]
Mar. 31, 2013
Teva Pharmaceutical Industries, Ltd. [Member]
Dec. 31, 2012
Teva Pharmaceutical Industries, Ltd. [Member]
Mar. 31, 2013
Teva Pharmaceutical Industries, Ltd. [Member]
September 21, 2009 Investment [Member]
Mar. 31, 2013
Teva Pharmaceutical Industries, Ltd. [Member]
January 19, 2011 Investment [Member]
Mar. 31, 2013
Teva Pharmaceutical Industries, Ltd. [Member]
December 7, 2012 Investment [Member]
Mar. 31, 2013
Teva Pharmaceutical Industries, Ltd. [Member]
December 27, 2012 Investment [Member]
Investment amount                                       $ 9,126,000   $ 3,500,000 $ 3,950,000 $ 750,000 $ 926,000
Shares issued 2,083,333 19,130,435 8,333,333 2,334,515 6,666,667 300,000 6,072,383 3,102,837 2,857,143 642,858 4,857,159 3,850,000 650,000 4,175,000 3,600,000     2,334,515 3,102,837 7,520,685   3,102,837 2,334,515 2,083,333  
Proceeds Remaining in Restricted Cash                                       919,680     178,301   741,379
Deferred Research and Development Arrangement (note 8)                               $ 1,472,629 $ 1,626,000     $ 741,379 $ 876,000       $ 741,379